Researchers Evaluate BCMA Therapies for Early Myeloma Care
New clinical studies explore integrating BCMA-directed treatments into earlier stages of multiple myeloma therapy.
Updated on Oct. 28, 2026 in Cancer
Medical researchers are evaluating the integration of BCMA-directed therapies into earlier-line treatment regimens for multiple myeloma. This approach aims to address the disease when it is less heterogeneous and before significant T-cell exhaustion occurs.
Why it matters
Using these therapies earlier may preserve BCMA expression, potentially improving the effectiveness of subsequent treatments like CAR T-cell therapy or bispecific antibodies.
The DREAMM-10 study is currently evaluating the use of belantamab mafodotin with a modified, lower-dose, and less frequent dosing schedule. The research requires ongoing ophthalmologic monitoring for all participating patients.
The players
DREAMM-10
This is a clinical study focused on evaluating the efficacy and dosing safety of belantamab mafodotin for multiple myeloma patients.
The details
The strategy involves combining BCMA-directed therapies with CD38-targeted agents to achieve multi-antigen targeting. By intervening earlier, clinicians hope to minimize T-cell exhaustion and better manage the progression of multiple myeloma.
Timeline
October 2026: Clinical panel discussion regarding BCMA therapy integration.
The Big Picture
The DREAMM-10 study marks a departure from traditional relapse-focused protocols by moving BCMA-directed treatments to earlier lines of care. This research shifts the paradigm toward using these therapies while the disease is less heterogeneous.
Patients may eventually see these therapies integrated into earlier care stages, potentially delaying the need for more intensive subsequent treatments. Those undergoing these therapies must adhere to baseline and regular ophthalmologic monitoring to ensure safety.
The takeaway
Moving BCMA-targeted therapies to earlier lines of care could fundamentally change how multiple myeloma is managed by preserving treatment options for the future. Patients and providers should focus on the necessity of strict ophthalmologic monitoring during these regimens.
Further reading
Learn more about advancements in Cancer treatment and research.
Source note: This article includes information reported by OncLive.
